| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 26.964 | 30.638 | 8.840 | 0 | 3.433 | 0 | 0 | 0 | 0 | - |
| Total Income - EUR | 28.038 | 31.864 | 9.278 | 0 | 3.465 | 0 | 0 | 0 | 0 | - |
| Total Expenses - EUR | 34.672 | 37.323 | 16.153 | 29.774 | 25.477 | 0 | 0 | 0 | 0 | - |
| Gross Profit/Loss - EUR | -6.634 | -5.459 | -6.874 | -29.774 | -22.012 | 0 | 0 | 0 | 0 | - |
| Net Profit/Loss - EUR | -7.469 | -6.072 | -6.996 | -29.774 | -22.046 | 0 | 0 | 0 | 0 | - |
| Employees | 2 | 1 | 1 | 2 | 2 | 0 | 0 | 0 | 0 | - |
Check the financial reports for the company - Genescreen S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 154 | 152 | 24 | 43 | 42 | 41 | 40 | 41 | 40 | - |
| Current Assets | 11.678 | 9.864 | 2.701 | 3.064 | 7.132 | 6.997 | 6.842 | 6.863 | 6.842 | - |
| Inventories | 5.847 | 5.548 | 1.236 | 0 | 3.602 | 3.534 | 3.455 | 3.466 | 3.456 | - |
| Receivables | 5.190 | 2.763 | 1.436 | 2.561 | 3.385 | 3.321 | 3.247 | 3.257 | 3.247 | - |
| Cash | 640 | 1.554 | 29 | 503 | 145 | 142 | 139 | 140 | 139 | - |
| Shareholders Funds | -19.001 | -24.816 | -31.392 | -60.332 | -81.210 | -79.670 | -77.903 | -78.145 | -77.908 | - |
| Social Capital | 90 | 89 | 88 | 344 | 337 | 331 | 323 | 324 | 323 | - |
| Debts | 30.832 | 34.832 | 34.123 | 63.438 | 88.384 | 86.708 | 84.786 | 85.049 | 84.791 | - |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4646 - 4646" | |||||||||
| CAEN Financial Year |
4773
|
|||||||||
Comments - Genescreen S.r.l.